Healthcare entity

uniQure

Company QURE

All 2 tracked stories fall under one category: market-trends. uniQure is most often covered alongside AMT-130, which appears in 2 of these 2 stories. The 109-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline.

Last mentioned: Aug 5, 2026

RSS updates
Share

Entity pulse

Recent coverage · uniQure

↑
2 stories
6 avg impact
50% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.

  • 50% positive
  • 50% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about uniQure

All 2 tracked stories fall under one category: market-trends. uniQure is most often covered alongside AMT-130, which appears in 2 of these 2 stories. The 109-day window averages about 0.1 stories each week. Source depth averages 2 original sources per story, versus 3.2 across the same-window beat baseline. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. uniQure appears in 2 tracked Healthcare stories published from March 3, 2026 through June 19, 2026.

Stories tracked
2
Per week
0.1
Sources per story
2

Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 540 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering uniQure. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Type B FDA Meeting Target

    Planned follow-up to define Phase III and regulatory path for AMT-130.

  2. AMT-260 Data Readout

    Expected clinical data from Phase I/IIa epilepsy study in H1 2026.

  3. Type A FDA Meeting

    Discussed AMT-130 approval pathway; alignment not yet reached.

  4. Fiscal Year End

    Closed 2025 with $622.5 million in liquidity.

Stories mentioning uniQure 2

uniQure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.